AGD10 Antibody
Description
ADAM10 Antibodies in Biomedical Research
ADAM10 (A Disintegrin And Metalloproteinase 10) is a transmembrane protease involved in ectodomain shedding of proteins like Notch, amyloid precursor protein (APP), and cytokines. Antibodies targeting ADAM10 are critical tools for studying its roles in cancer, Alzheimer's disease, and immune regulation.
Key Antibody Characteristics (CAB10438 Example)
Research Applications & Findings
-
B Cell Regulation: ADAM10 deficiency in B cells (ADAM10<sup>B-/-</sup> mice) causes impaired germinal center formation, reduced follicular Th cells, and altered lymph node structures, significantly diminishing antibody responses to T-dependent antigens .
-
Cancer Targeting: The 8C7 monoclonal antibody selectively binds active ADAM10 conformers on tumor cells. Conjugated to cytotoxic drugs, it inhibits xenograft growth in mice while sparing normal tissues .
-
Mechanistic Insights: ADAM10 modulates B cell localization and chemokine expression in lymphoid tissues, establishing it as a master regulator of humoral immunity .
AG10: A Transthyretin (TTR) Stabilizer
AG10 is an oral small-molecule kinetic stabilizer of transthyretin, not an antibody. It shows promise for treating transthyretin amyloidosis (ATTR).
Pharmacological Profile
Key Findings
-
Mechanism: Binds tetrameric TTR with negative cooperativity (K<sub>d1</sub>=0.7 μM, K<sub>d2</sub>=75 μM), preventing dissociation into amyloidogenic monomers .
-
Efficacy: Completely inhibits acid-mediated dissociation of pathogenic V122I-TTR mutants at 10 μM .
-
Safety: No hepatic/renal toxicity observed in phase 1 trials (up to 800 mg doses) .
Critical Nomenclature Distinction
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Research indicates that IDN2 interacts with RPA, facilitating the release of RPA from single-stranded DNA tails. This interaction subsequently promotes the recruitment of RAD51 at DSB sites, ultimately contributing to DSB repair. PMID: 28223440
- AGD10 Antibody's target plays a role in root hair and pollen tube growth, likely through the regulation of Arabidopsis ARF1 and ARF1-like protein U5 activity. PMID: 16731582
- AtRPA1a is essential for class I crossover formation but is not required for meiotic DNA break repair. PMID: 19153602
Q&A
Here’s a structured collection of FAQs tailored for academic researchers working with ADAM10 antibodies, based on analysis of peer-reviewed methodologies and experimental data from diverse sources:
Advanced Research Questions
How to resolve discrepancies in ADAM10 antibody molecular weight observations?
-
Post-translational modifications: Glycosylation or cleavage (e.g., 120 kDa precursor → 90 kDa active form) .
-
Protease inhibitors: Include in lysis buffers to prevent artifactual degradation.
-
Alternative isoforms: Test splice variants using isoform-specific primers .
Does antibody affinity directly correlate with functional efficacy in ADAM10 studies?
-
Threshold effects: Anti-GM1 antibodies with KD <1 nM induced neuropathy vs. >10 nM in controls .
-
Context dependence: High affinity may hinder tissue penetration; balance with valency (e.g., IgG vs. Fab fragments) .
How to address contradictory stabilization data across ADAM10 assays?
Data Interpretation Guidelines
-
Unexpected bands: Re-run with KO controls (e.g., 19 kDa band in ab124695 may indicate degradation) .
-
Stabilization metrics: Use ≥90% threshold (as in AG10’s TTR stabilization) for clinical relevance .
-
Affinity maturation: Compare recombinant vs. hybridoma-derived antibodies (1–2 log KD differences) .
